Economic evidence in multiple sclerosis: A review

被引:24
作者
Kobelt G. [1 ]
机构
[1] European Health Economics, Spéracèdes
关键词
Public Health; Multiple Sclerosis; Economic Evidence;
D O I
10.1007/s10198-005-0289-y
中图分类号
学科分类号
摘要
[No abstract available]
引用
收藏
页码:S54 / S62
页数:8
相关论文
共 33 条
[1]  
Hauser S., Multiple sclerosis and other demyelinating diseases, Harrison's Principles of Internal Medicine, pp. 2281-2294, (1994)
[2]  
Dean G., How many people in the world have multiple sclerosis?, Neuroepidemiology, 13, (1994)
[3]  
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43, pp. 655-661, (1993)
[4]  
Jacobs L., Cookfair D., Rudick R., Herndon R., Richert J., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Ann Neurol, 39, pp. 285-294, (1996)
[5]  
Randomised double-blind placebo-controlled study of interferon beta-1a in relasping/remitting multiple sclerosis, Lancet, 352, pp. 1498-1504, (1998)
[6]  
Johnson K., Et al., Copolymer 1 in relapsing-remitting multiple sclerosis, Neurology, 50, pp. 701-708, (1998)
[7]  
Interferon beta-1B delays progression of disability in secondary progressive multiple sclerosis: Results of a European multicentre randomised Study, Lancet, pp. 1491-1497, (1998)
[8]  
Lublin F., Reingold S.C., Defining the clinical course of multiple sclerosis: Results of an international survey, Neurology, 46, pp. 907-911, (1996)
[9]  
Weinshenker B., Et al., The natural history of multiple sclerosis I and II, Brain, 114, pp. 1045-1065, (1991)
[10]  
Kurtzke J., A new scale for evaluating disability in multiple sclerosis, Neurology, 5, pp. 580-583, (1955)